Vernalis PLC (VNLPY.PK): Results for the Year Ended 31 December 2012
4/10/2013 9:48:04 AM
More...
|
First Product in Tris Pharma, Inc.'s Collaboration With Vernalis PLC (VNLPY.PK) Achieves Proof-of-Concept, Triggering Milestone Payment to Tris
3/12/2013 9:32:47 AM
More...
|
Vernalis PLC (VNLPY.PK) and Servier Extend Oncology Collaboration
3/6/2013 2:48:37 PM
More...
|
First Product in Vernalis PLC (VNLPY.PK) Cough Cold Pipeline Achieves Proof-of-Concept
3/6/2013 11:57:43 AM
More...
|
Vernalis PLC (VNLPY.PK) Receives a Further $2.5 Million Payment From Its Drug Discovery Collaboration With Genentech (RHHBY)
3/4/2013 11:44:35 AM
More...
|
Vernalis PLC (VNLPY.PK) Receives $1.5 Million Milestone Payment From Drug Discovery Collaboration With Genentech (RHHBY)
2/4/2013 12:49:03 PM
More...
|
Vernalis PLC (VNLPY.PK) and Servier Achieve Research Milestone in Third Oncology Collaboration
1/7/2013 11:37:21 AM
More...
|
Vernalis PLC (VNLPY.PK) and H. Lundbeck A/S (LUN.CO) Achieve Third Research Milestone
1/2/2013 10:11:45 AM
More...
|
Positive Results Achieved in Vernalis PLC (VNLPY.PK)' Receptor Occupancy Study of V8144 for Parkinson's Disease and Other CNS Indications
12/12/2012 9:42:30 AM
More...
|
Vernalis PLC (VNLPY.PK) and Servier Achieve Research Milestone in First Oncology Collaboration
9/20/2012 10:16:16 AM
More...
|
|